The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRH Regulatory News (CRH)

Share Price Information for CRH (CRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,780.00
Bid: 6,808.00
Ask: 6,816.00
Change: 336.00 (5.21%)
Spread: 8.00 (0.118%)
Open: 6,638.00
High: 6,808.00
Low: 6,556.00
Prev. Close: 6,444.00
CRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transition to US Primary Listing Approved

8 Jun 2023 14:20

RNS Number : 1489C
CRH PLC
08 June 2023
 

Press Release

Transition to US Primary Listing Approved

CRH plc, the leading provider of building materials solutions, is pleased to announce that shareholders overwhelmingly approved the unanimous recommendation of the Board and management team to transition to a US primary listing on the New York Stock Exchange (NYSE) at an Extraordinary General Meeting held earlier today.

The Group will retain a standard listing on the London Stock Exchange (LSE) and will de-list from Euronext Dublin. The changes are expected to take effect on or around 25 September 2023.

We believe a US primary listing will bring increased commercial, operational and acquisition opportunities for our business, further accelerating our successful integrated solutions strategy and delivering even higher levels of profitability, returns and cash for our shareholders.

North America represents approximately 75% of Group EBITDA and the US is expected to be a key driver of future growth for CRH due to continued economic expansion, a growing population and significant construction needs.

As the leading building materials solutions business in North America, CRH is uniquely positioned to capitalise on the strong growth opportunities in the US construction market, underpinned by long-term structural tailwinds from federal, state and municipal funding support.

Albert Manifold, Chief Executive of CRH, said: "We are pleased to see such strong shareholder support for the listing transition as it marks an important milestone in our development and will enable CRH to fully participate in the significant growth opportunities that lie ahead".

****

Contact CRH at Dublin 404 1000 (+353 1 404 1000)

Albert Manifold

Chief Executive

Jim Mintern

Chief Financial Officer

Frank Heisterkamp

Director of Capital Markets & ESG

Tom Holmes

Head of Investor Relations

 

 

About CRH

CRH (LSE: CRH, ISE: CRG, NYSE: CRH) is the leading provider of building materials solutions that build, connect and improve our world. Employing c.75,800 people at c.3,160 locations in 29 countries, CRH has market leadership positions in both North America and in Europe. As the essential partner for road and critical utility infrastructure, commercial building projects and outdoor living solutions, CRH's unique offering of materials, products and value-added services helps to deliver a more resilient and sustainable built environment. A Fortune 500 company, CRH is a constituent member of the FTSE 100 Index, the EURO STOXX 50 Index, the ISEQ 20 and the Dow Jones Sustainability Index (DJSI) Europe. The company is ranked among sector leaders by Environmental, Social and Governance (ESG) rating agencies. CRH's American Depositary Shares are listed on the NYSE. For more information visit www.crh.com.

 

Disclaimer / Forward-Looking Statements

In order to utilise the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, CRH public limited company (the "Company"), and its subsidiaries (collectively, "CRH" or the "Group") is providing the following cautionary statement.

This document contains statements that are, or may be deemed to be forward-looking statements with respect to the financial condition, results of operations, business, viability and future performance of CRH and certain plans and objectives of CRH, including but not limited to the statements regarding the expected execution and/or anticipated benefits of a transition to a US primary listing. These forward-looking statements may generally, but not always, be identified by the use of words such as "will", "believe", "continues", "is expected to", or similar expressions. These forward-looking statements include all matters that are not historical facts or matters of fact at the date of this document.

Forward-looking statements are subject to risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and/or are beyond the Company's control or precise estimate. Such risks, uncertainties and other factors include, but are not limited to, plans and expectations related to the execution and anticipated financial and operational results of a US primary listing, expectations related to the US as a driver for future growth, and plans and expectations related to government policies. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different, including risks and uncertainties relating to CRH described under "Principal Risks and Uncertainties (Risk Factors)" of the Company's Annual Report and Form 20-F for the year ended December 31, 2022.

You are cautioned not to place undue reliance on any forward-looking statements. These forward-looking statements are made as of the date of this document. The Company expressly disclaims any obligation or undertaking to publicly update or revise these forward-looking statements other than as required by applicable law.

The forward-looking statements in this document do not constitute reports or statements published in compliance with any of Regulations 6 to 8 of the Transparency (Directive 2004/109/EC) Regulations 2007 (as amended).

Registered Office: No 12965. Registered Office: 42 Fitzwilliam Square, Dublin 2, R02 R279, Ireland

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUGUQUPWGWR
Date   Source Headline
10th May 202412:00 pmRNSForm 10-Q for the quarter ended March 31, 2024
10th May 20249:45 amRNSTransaction in Own Shares
9th May 20249:30 amRNSTransaction in Own Shares
8th May 20249:30 amRNSTransaction in Own Shares
7th May 20249:45 amRNSTransaction in Own Shares
7th May 20249:30 amRNSTransaction in Own Shares
3rd May 20249:45 amRNSTransaction in Own Shares
3rd May 20249:30 amRNSTransaction in Own Shares
2nd May 20249:00 amRNSTransaction in Own Shares
1st May 20249:00 amRNSTransaction in Own Shares
30th Apr 20244:00 pmRNSTotal Voting Rights
30th Apr 20249:30 amRNSTransaction in Own Shares
29th Apr 20249:30 amRNSTransaction in Own Shares
25th Apr 20245:00 pmRNSDirector/PDMR Shareholding
25th Apr 20244:30 pmRNSAGM Statement
25th Apr 20248:30 amRNSTransaction in Own Shares
4th Apr 20244:15 pmRNSTransaction in Own Shares
2nd Apr 20244:10 pmRNSBlock listing Interim Review
2nd Apr 20243:08 pmRNSTotal Voting Rights
27th Mar 20245:30 pmRNSDirector/PDMR Shareholding
22nd Mar 20244:30 pmRNSDirector/PDMR Shareholding
20th Mar 20249:30 amRNSTransaction in Own Shares
19th Mar 20249:40 amRNSTransaction in Own Shares
19th Mar 20249:15 amRNSTransaction in Own Shares
15th Mar 20243:15 pmRNSNotice of AGM
15th Mar 20249:30 amRNSTransaction in Own Shares
14th Mar 20249:30 amRNSTransaction in Own Shares
13th Mar 20249:30 amRNSTransaction in Own Shares
12th Mar 20249:15 amRNSTransaction in Own Shares
11th Mar 20249:30 amRNSTransaction in Own Shares
8th Mar 20245:00 pmRNSDirector/PDMR Shareholding
8th Mar 20249:30 amRNSTransaction in Own Shares
7th Mar 20249:30 amRNSTransaction in Own Shares
6th Mar 20248:45 amRNSTransaction in Own Shares
5th Mar 20245:30 pmRNSDirector/PDMR Shareholding
5th Mar 20249:45 amRNSTransaction in Own Shares
4th Mar 20244:00 pmRNSTransaction in Own Shares
4th Mar 20249:45 amRNSTransaction in Own Shares
1st Mar 20243:00 pmRNSTransaction in Own Shares
29th Feb 20243:00 pmRNSTotal Voting Rights
29th Feb 202412:05 pmRNS2023 Annual Report on Form 10-K
29th Feb 20248:45 amRNSTransaction in Own Shares
28th Feb 20249:30 amRNSTransaction in Own Shares
27th Feb 20249:30 amRNSTransaction in Own Shares
26th Feb 20249:30 amRNSTransaction in Own Shares
23rd Feb 20249:30 amRNSTransaction in Own Shares
23rd Feb 20247:05 amRNS5% Preference Shares - Listings Update
22nd Feb 20249:30 amRNSTransaction in Own Shares
21st Feb 20249:30 amRNSTransaction in Own Shares
21st Feb 20247:05 amRNS5% Preference Shares - Listings Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.